Literature DB >> 17396143

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Dengfeng Cao1, Qian Zhang, Lee Shun-Fune Wu, Safia N Salaria, Jordan W Winter, Ralph H Hruban, Michael S Goggins, James L Abbruzzese, Anirban Maitra, Linus Ho.   

Abstract

Maspin (SERPINB5), a serine proteinase inhibitor, was first identified as a potential tumor suppressor on the basis of its differential expression between normal mammary epithelial cells and human breast carcinoma cell lines. Recent studies have shown that maspin might be a prognostic tumor marker. Pancreatic ductal adenocarcinoma acquires maspin expression through hypomethylation of the maspin promoter. However, no study has investigated the prognostic significance of maspin expression in pancreatic ductal adenocarcinomas. In this study, we investigated maspin protein expression in a large series of 223 surgically resected pancreatic ductal adenocarcinomas using immunohistochemical staining and high throughput tissue microarrays. Maspin expression was correlated with postoperative survival and other clinicopathologic factors. Maspin was detected in 209 of these 223 (94% cases) pancreatic ductal adenocarcinomas including 39 (18% cases) focal (5-50% tumor cells) and 170 (76% cases) diffuse (>50% tumor cells). Fourteen (or 6% cases) pancreatic ductal adenocarcinomas did not show maspin expression by immunohistochemical staining (<5% tumor cells). Normal ductal epithelium is not labeled with maspin. Overexpression of maspin in pancreatic ductal adenocarcinoma is associated with worse postoperative survival especially in patients whose tumors exhibit diffuse expression of maspin. After adjusting other clinicopathologic factors, maspin expression remains to be an independent adverse prognosticator for postoperative survival. Maspin expression is not associated with patient age, gender, tumor size, tumor pathologic stage, lymph node status, and vascular invasion or perineural invasion. Nuclear labeling of maspin is associated with better tumor differentiation although this staining pattern is not associated with a better prognosis. In addition, maspin overexpression is also observed in 48% low-grade (grades 1a and 1b) pancreatic intraepithelial neoplasias (PanINs) and 78% high-grade (grades 2 and 3) PanINs, suggesting that maspin upregulation occurs early during the multi-step progression model of pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17396143     DOI: 10.1038/modpathol.3800772

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  35 in total

Review 1.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

2.  Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma.

Authors:  Chenxi Tian; Daniel Öhlund; Steffen Rickelt; Tommy Lidström; Ying Huang; Liangliang Hao; Renee T Zhao; Oskar Franklin; Sangeeta N Bhatia; David A Tuveson; Richard O Hynes
Journal:  Cancer Res       Date:  2020-02-06       Impact factor: 12.701

3.  SLC5A8 nuclear translocation and loss of expression are associated with poor outcome in pancreatic ductal adenocarcinoma.

Authors:  James Helm; Domenico Coppola; Vadivel Ganapathy; Mark Lloyd; Barbara A Centeno; Dung-Tsa Chen; Mokenge P Malafa; Jong Y Park
Journal:  Pancreas       Date:  2012-08       Impact factor: 3.327

4.  Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.

Authors:  Ji Kon Ryu; Seung-Mo Hong; Collins A Karikari; Ralph H Hruban; Michael G Goggins; Anirban Maitra
Journal:  Pancreatology       Date:  2010-03-20       Impact factor: 3.996

5.  Pdx1 expression in pancreatic precursor lesions and neoplasms.

Authors:  Jason Y Park; Seung-Mo Hong; David S Klimstra; Michael G Goggins; Anirban Maitra; Ralph H Hruban
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-10

Review 6.  Current status of molecular markers for early detection of sporadic pancreatic cancer.

Authors:  Subhankar Chakraborty; Michael J Baine; Aaron R Sasson; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2010-10-01

7.  Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia.

Authors:  Jan-Bart M Koorstra; Seung-Mo Hong; Chanjuan Shi; Alan K Meeker; Ji Kon Ryu; George Johan A Offerhaus; Michael G Goggins; Ralph H Hruban; Anirban Maitra
Journal:  Mod Pathol       Date:  2009-08-07       Impact factor: 7.842

8.  Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma.

Authors:  Giuseppe Aprile; Claudio Avellini; Michele Reni; Micol Mazzer; Luisa Foltran; Diego Rossi; Stefano Cereda; Emiliana Iaiza; Gianpiero Fasola; Andrea Piga
Journal:  Tumour Biol       Date:  2012-09-25

9.  TMEM45A, SERPINB5 and p16INK4A transcript levels are predictive for development of high-grade cervical lesions.

Authors:  Anna Manawapat-Klopfer; Louise T Thomsen; Peter Martus; Christian Munk; Rainer Russ; Hans Gmuender; Kirsten Frederiksen; Juliane Haedicke-Jarboui; Frank Stubenrauch; Susanne K Kjaer; Thomas Iftner
Journal:  Am J Cancer Res       Date:  2016-07-01       Impact factor: 6.166

10.  CRABP-II is a highly sensitive and specific diagnostic molecular marker for pancreatic ductal adenocarcinoma in distinguishing from benign pancreatic conditions.

Authors:  Wenbin Xiao; Hong Hong; Amad Awadallah; Shuiliang Yu; Lan Zhou; Wei Xin
Journal:  Hum Pathol       Date:  2014-01-31       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.